Your browser doesn't support javascript.
loading
Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients.
Aparicio-Minguijón, Eduardo; Boán, Jorge; Terrón, Antonio; Heredia, Carlos; Puente, Cristina; Pérez-Jacoiste Asín, Asunción; Orellana, M Ángeles; Domínguez, Laura; Caro, José Manuel; López-Gude, M Jesús; Aguilar-Blanco, Eva María; Eixerés-Esteve, Andrea; López-Medrano, Francisco.
Afiliación
  • Aparicio-Minguijón E; Department of Internal Medicine, University Hospital '12 de Octubre', Spain. Electronic address: edu.ap93@gmail.com.
  • Boán J; Department of Internal Medicine, University Hospital '12 de Octubre', Spain.
  • Terrón A; Department of Internal Medicine, University Hospital '12 de Octubre', Spain.
  • Heredia C; Department of Internal Medicine, University Hospital '12 de Octubre', Spain.
  • Puente C; Department of Internal Medicine, University Hospital '12 de Octubre', Spain.
  • Pérez-Jacoiste Asín A; Department of Internal Medicine, University Hospital '12 de Octubre', Spain.
  • Orellana MÁ; Department of Microbiology, University Hospital '12 de Octubre', Spain.
  • Domínguez L; Department of Cardiology, University Hospital '12 de Octubre', Spain.
  • Caro JM; Department of Pharmacy, University Hospital '12 de Octubre', Spain.
  • López-Gude MJ; Department of Cardiac Surgery, University Hospital '12 de Octubre', Spain.
  • Aguilar-Blanco EM; Department of Cardiac Surgery, University Hospital '12 de Octubre', Spain.
  • Eixerés-Esteve A; Department of Cardiac Surgery, University Hospital '12 de Octubre', Spain.
  • López-Medrano F; Unit of Infectious Diseases, University Hospital '12 de Octubre', Instituto de Investigación Sanitaria Hospital '12 de Octubre' (imas12), School of Medicine, Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Spain.
Article en En | MEDLINE | ID: mdl-38902152
ABSTRACT

OBJECTIVES:

This study aimed to evaluate the effectiveness of dalbavancin as sequential therapy in patients with infective endocarditis (IE) due to gram positive bacteria (GPB) in a real-life heterogenous cohort with comorbid patients.

METHODS:

A single center retrospective cohort study including all patients with definite IE treated with dalbavancin between January 2017 and February 2022 was developed. A 6-month follow-up was performed. The main outcomes were clinical cure rate, clinical and microbiological relapse, 6-month mortality, and adverse effects (AEs) rate.

RESULTS:

The study included 61 IE episodes. The median age was 78.5 years (interquartile range [IQR] 63.2-85.2), 78.7% were male, with a median Charlson comorbidity index of 7 (IQR 4-9) points. Overall, 49.2% suffered native valve IE. The most common microorganism was Staphylococcus aureus (26.3%) followed by Enterococcus faecalis (21.3%). The median duration of initial antimicrobial therapy and dalbavancin therapy were 27 (IQR 20-34) and 14 days (IQR 14-28) respectively. The total reduction of hospitalization was 1090 days. The most frequent dosage was 1500mg of dalbavancin every 14 days (96.7%). An AE was detected in 8.2% of patients, only one (1.6%) was attributed to dalbavancin (infusion reaction). Clinical cure was achieved in 86.9% of patients. One patient (1.6%) with Enterococcus faecalis IE suffered relapse. The 6-month mortality was 11.5%, with only one IE-related death (1.6%).

CONCLUSION:

This study shows a high efficacy of dalbavancin in a heterogeneous real-world cohort of IE patients, with an excellent safety profile. Dalbavancin allowed a substantial reduction of in-hospital length of stay.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Enferm Infecc Microbiol Clin (Engl Ed) Año: 2024 Tipo del documento: Article Pais de publicación: España

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Enferm Infecc Microbiol Clin (Engl Ed) Año: 2024 Tipo del documento: Article Pais de publicación: España